scholarly journals The etiologic spectrum of head and neck squamous cell carcinoma in young patients

Oncotarget ◽  
2016 ◽  
Vol 7 (40) ◽  
pp. 66226-66238 ◽  
Author(s):  
Xin Liu ◽  
Xiao-lei Gao ◽  
Xin-hua Liang ◽  
Ya-ling Tang
2011 ◽  
Vol 130 (8) ◽  
pp. 1806-1812 ◽  
Author(s):  
H.S. van Monsjou ◽  
M.L.F. van Velthuysen ◽  
M.W.M. van den Brekel ◽  
E.S. Jordanova ◽  
C.J.M. Melief ◽  
...  

1990 ◽  
Vol 36 (5) ◽  
pp. 1296-1307
Author(s):  
Mitsuhiro NAKAZAWA ◽  
Motohiro TSUJINO ◽  
Tomoji MORIYAMA ◽  
Tetsurou SUMI ◽  
Yoshihide MORI ◽  
...  

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1787
Author(s):  
Panagiota Economopoulou ◽  
Ioannis Kotsantis ◽  
Amanda Psyrri

HPV-related head and neck squamous cell carcinoma (HNSCC) has emerged as a diverse clinical and biological disease entity, mainly in young patients with oropharyngeal tumors who are nonsmokers and nondrinkers. Indeed, during the past few years, the pendulum has shifted towards a new epidemiological reality, the “HPV pandemic”, where the majority of oropharyngeal squamous cell carcinomas (OPSCCs) are attributed to HPV. The oncogenic potential of the virus is associated to its capacity of integrating oncogenes E6 and E7 into the host cell, leading to the inactivation of several tumor suppressor genes, such as Rb. HPV status can affect prognosis in OPSCC, but its role as a predictive biomarker remains to be elucidated. Given the favorable prognosis associated with HPV-positive disease, the concept of de-escalation treatment strategies has been developed with the primary intent being the reduction of treatment-related long-term toxicities. In this review, we aim to depict current data regarding treatment de-escalation in HPV-associated OPSCC and discuss ongoing clinical trials.


2000 ◽  
Vol 122 (2) ◽  
pp. 253-258 ◽  
Author(s):  
Peter D. Lacy ◽  
Jay F. Piccirillo ◽  
Michael G. Merritt ◽  
Maria R. Zequeira

Most head and neck squamous cell carcinoma patients are elderly, with few younger than 40 years. Controversy exists in the literature regarding outcomes for younger patients. The goal of this research project was to compare baseline features and outcomes for young patients (≤40 years), middle-aged patients (41–64 years), and old patients (≥65 years). To investigate the relationship between age and important presenting features and outcomes, 1160 recently diagnosed patients first treated at Washington University between 1980 and 1991 were identified from an existing database. Full 5-year survival information was available for 1030 patients (89%). Overall, the 5-year survival rate was 46% (478/1030); young patients (65%, 26/40) had a significantly better survival rate than middle-aged (52%, 292/566) or old patients (38%, 160/424) (χ2 = 24.5; P = 0.001). Survival was also related to smoking, comorbidity, primary site, TNM stage, and nodal disease. Age remained a significant factor even after we controlled for these other factors. Young patients developed fewer recurrent and new primary tumors. We conclude that young patients have a much better overall prognosis than older patients. The reasons for this difference are unclear, but it appears that the impact of age goes beyond an actuarial effect.


Oral Oncology ◽  
2009 ◽  
Vol 45 (9) ◽  
pp. 777-782 ◽  
Author(s):  
A.M.B. De Paula ◽  
L.R. Souza ◽  
L.C. Farias ◽  
G.T.B. Corrêa ◽  
C.A.C. Fraga ◽  
...  

Oral Oncology ◽  
2013 ◽  
Vol 49 (12) ◽  
pp. 1097-1102 ◽  
Author(s):  
Hester S. van Monsjou ◽  
Volkert B. Wreesmann ◽  
Michiel W.M. van den Brekel ◽  
Alfons J.M. Balm

2005 ◽  
Vol 133 (2) ◽  
pp. P143-P143
Author(s):  
S SMITHJR ◽  
A FLEMING ◽  
N PEIFFER ◽  
C PAUL ◽  
A AGRAWAL

Head & Neck ◽  
1998 ◽  
Vol 20 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Bhuvanesh Singh ◽  
Mahesh Bhaya ◽  
Marc Zimbler ◽  
Jordan Stern ◽  
J. Thomas Roland ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document